LA de Jong, J Groeneveld, J Stevanovic, H Rila… - PLoS ONE, 2019 - ncbi.nlm.nih.gov
Objective We aim to evaluate the cost-effectiveness of the NOAC apixaban versus other
NOACs (dabigatran, edoxaban and rivaroxaban) and VKA, for stroke prevention in patients …